Medication info

Empagliflozin and Metformin Extended Release Tablets 12.5/1000 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride with Colloidal Anhydrous Silica›1010mg / 1 tabletEmpagliflozin›12.5mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Bright yellow oval extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501914 · Approved 2025.07.25

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
When used as part of antidiabetic therapy, the dosage of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken once daily with a meal in the evening. Take 1 tablet of this medication 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medication 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medication whole without splitting, crushing, grinding, or chewing it. For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medications such as insulin, the recommended initial total daily dose when taking this medication is empagliflozin 10 mg and their existing metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medication should receive their existing doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. Because dosage adjustment based on renal function may be necessary, assessment of renal function is recommended before starting this medication and periodically during treatment. No dosage adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medication may be used by adjusting the dose of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medication must be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Abnormal glucose control
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes who are treated with both empagliflozin and metformin. Patients with existing cardiovascular disease who have insufficient glycemic control should consult a specialist for clinical trial information. This medication effectively aids in glycemic management and contributes to the treatment of diabetes.

How to take

Adult dose

When used as part of antidiabetic therapy, the dosage of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken once daily with a meal in the evening. Take 1 tablet of this medication 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medication 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medication whole without splitting, crushing, grinding, or chewing it. For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medications such as insulin, the recommended initial total daily dose when taking this medication is empagliflozin 10 mg and their existing metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medication should receive their existing doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. Because dosage adjustment based on renal function may be necessary, assessment of renal function is recommended before starting this medication and periodically during treatment. No dosage adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medication may be used by adjusting the dose of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medication must be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used for the treatment of diabetes and should not be administered to patients with impaired renal function or severe liver disease. This medication can cause a rare but very serious side effect known as lactic acidosis; therefore, if the patient is in a state of dehydration, severe infection, or decreased heart function, administration should be discontinued. During the course of treatment, hypoglycemic symptoms may occur, so caution is particularly needed when used in conjunction with insulin or other antidiabetic agents. Urinary tract infections or genital infections may occur, so if symptoms of infection develop, consultation with healthcare providers should occur immediately. This medication can cause a decrease in fluid volume, so caution should be exercised regarding blood pressure and fluid status in patients at high risk of dehydration or the elderly. Pregnant or breastfeeding women are advised not to use this medication, especially during pregnancy where insulin therapy is recommended. If surgery is planned or if examinations using iodine contrast media are to be performed, administration of this medication should be discontinued for a certain period before and after the examination. This medication must be swallowed whole and should not be chewed or crushed. Vitamin B12 deficiency may occur, so it is necessary to monitor blood levels of vitamin B12 regularly during prolonged use. In case of overdose, severe side effects such as lactic acidosis could occur, so dosage must be strictly followed, and any unusual symptoms should be reported to a healthcare provider immediately. It is advisable to avoid alcohol consumption during treatment, as well as irregular meals or excessive exercise. Elderly patients may have decreased renal function, necessitating regular kidney function tests, while ensuring they do not exceed the maximum dosage. This medication may interact with other drugs, so it is essential to inform healthcare providers about any other medications being taken. Caution is required during activities such as driving or operating machinery while taking this medication.

Side effects

  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased vitamin B12 and deficiency
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • nausea
  • vomiting
Show 164 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • itching
  • rash
  • hives
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • perineal necrosis
  • chronic gastritis
  • various neurological disorders
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • rash
  • hives
  • angioedema
  • perineal necrosis
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • gastrointestinal bleeding
  • headache
  • dizziness
  • insomnia
  • anxiety
  • hyperglycemia
  • hyponatremia
  • weight loss
  • vulvar pruritus
  • genital pruritus
  • glaucoma
  • diabetic retinopathy
  • cough
  • dyspnea
  • angina pectoris
  • hypertension
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular disorders
  • peripheral artery occlusive disease
  • unstable angina
  • dysmenorrhea
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • dysmenorrhea
  • positional vertigo
  • hematuria
  • urinary stones
  • ureteral calculi
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • urinary abnormalities
  • cervicitis
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • cervicitis
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • obesity
  • sequelae
  • diabetes mellitus
  • hyperlipidemia
  • dyslipidemia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • exudative retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • skin lacerations
  • rib fractures
  • iliotibial band syndrome
  • limb injuries
  • bruising
  • concussion
  • corneal abrasion
  • falls
  • hand fractures
  • iliotibial band syndrome
  • open globe injury
  • pelvic fractures
  • road traffic accidents
  • splenic injury
  • sternum fracture
  • palpitations

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture; therefore, it should be stored in a closed container. The storage temperature should ideally be maintained between 1 to 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Bright yellow oval extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.